CareDx to Divest Lab Products Business for $170 Million, Reports Strong Q1 2026 Growth
CareDx, Inc. has announced a definitive agreement to sell its Lab Products business to Eurobio Scientific for $170 million in cash. The decision marks a significant strategic shift as CareDx sharpens its focus on its core Precision Medicine Testing Services and Patient and Digital Solutions.
The divestiture is designed to streamline operations, enhance financial flexibility, and support long-term margin expansion. By exiting a business segment with a distinct operational model, CareDx aims to concentrate resources on higher-growth, service-oriented segments aligned with its primary expertise in transplant diagnostics and patient care.
The transaction has received approval from the boards of directors of both companies and is expected to close by the end of the third quarter of 2026, subject to regulatory review, including approval related to the sale of CareDx’s Swedish entity.
Understanding the Lab Products Business
CareDx’s Lab Products division primarily consists of in vitro diagnostic (IVD) kits used in transplant medicine. These include:
- PCR-based kits for rapid deceased donor HLA typing
- Next-generation sequencing (NGS)-based kits for transplant recipient HLA typing
- NGS-based monitoring assays for transplant patients outside North America
While the Lab Products business operates globally, it differs significantly from CareDx’s U.S.-focused testing services model. It requires specialized manufacturing, regulatory compliance across multiple jurisdictions, and a distinct commercial strategy.
Because of these differences, CareDx determined that divesting the segment would allow for a simpler operating model and more efficient allocation of capital toward its core business areas.
Strategic Benefits of the Divestiture
The agreement is expected to deliver multiple strategic advantages for CareDx:
1. Sharper Strategic Focus
By divesting the Lab Products unit, CareDx can concentrate on its core strengths—precision diagnostic testing services and digital patient solutions. These segments have demonstrated strong growth and align closely with the company’s long-term vision.
2. Simplified Operating Model
Removing a business with different operational requirements reduces complexity, enabling more streamlined decision-making and execution.
3. Improved Financial Flexibility
The $170 million cash inflow provides CareDx with additional resources to invest in growth initiatives, pursue acquisitions, or return capital to shareholders.
4. Margin Expansion Opportunities
Focusing on higher-margin service-based offerings is expected to support Adjusted EBITDA (AEBITDA) margin expansion over time.
Ongoing Collaboration with Eurobio Scientific
Despite the divestiture, CareDx will maintain a strategic relationship with Eurobio Scientific. As part of the agreement:
- CareDx will provide transition services for at least six months following the closing
- Eurobio Scientific will grant CareDx exclusive, perpetual rights to distribute certain post-transplant monitoring IVD tests in North America
This includes distribution rights for AlloSeq cfDNA, the IVD kit version of CareDx’s AlloSure dd-cfDNA test, which is widely recognized in transplant diagnostics.
The continued collaboration ensures continuity for customers and patients while allowing both companies to leverage their respective strengths.
Leadership Perspective on the Transaction
John Hanna, President and CEO of CareDx, emphasized the strategic importance of the divestiture. He noted that the company’s solution-selling approach is delivering strong results, particularly in its core segments.
According to Hanna, the move enables CareDx to double down on areas where it is seeing meaningful traction and growth. He also highlighted the long-standing partnership with Eurobio Scientific, expressing confidence in their ability to successfully manage and expand the Lab Products business globally.
Strong Preliminary Financial Results for Q1 2026
Alongside the announcement, CareDx shared preliminary financial results for the first quarter of 2026, indicating robust growth across key metrics.
Revenue Performance
- Total revenue reached approximately $118 million
- This represents a 39% increase compared to the same period last year
Testing Services Growth
- Testing service revenue was approximately $91 million
- Year-over-year growth of 48%
- Testing volume reached around 54,900, up 17%
Patient and Digital Solutions
- Revenue totaled approximately $16 million
- Growth of 33% year-over-year
Lab Products Segment
- Revenue was approximately $10 million
- Declined by 4% year-over-year, reinforcing the rationale for divestiture
Average Revenue Per Test
- Approximately $1,660 per test
- Includes about $14 million in prior period revenue
Cash Position
- Cash, cash equivalents, and marketable securities stood at approximately $198 million as of March 31, 2026
These figures highlight strong momentum in CareDx’s core business segments, particularly Testing Services, which continues to be a major growth driver.
Capital Allocation and Future Growth Strategy
CareDx plans to deploy proceeds from the transaction in a disciplined manner, consistent with its historical approach to capital allocation. Key priorities include:
- Investing in organic growth initiatives within Precision Medicine Testing Services
- Exploring strategic acquisitions that align with its Precision Diagnostics Solutions model
- Potentially returning capital to shareholders
The company remains focused on building a scalable, high-growth platform centered on advanced diagnostics and patient-centric solutions.
Regulatory and Closing Timeline
The transaction is subject to regulatory approvals, including a review in Sweden due to the involvement of CareDx’s Swedish entity. Both parties anticipate completing the deal by the end of CareDx’s third quarter in 2026.
CareDx also noted that the preliminary financial results are subject to final adjustments as part of its standard quarterly closing procedures. The company expects to provide more detailed guidance during its official earnings call scheduled for April 28, 2026.
CareDx’s decision to divest its Lab Products business represents a clear strategic pivot toward its core strengths in precision medicine and transplant diagnostics. The move not only simplifies the company’s operations but also enhances its ability to invest in high-growth areas.
Coupled with strong preliminary financial performance in the first quarter of 2026, the divestiture positions CareDx for continued expansion and improved profitability. As the company sharpens its focus and reallocates resources, it appears well-positioned to capitalize on the growing demand for advanced diagnostic solutions in transplant care.
About CareDx
CareDx is a precision medicine company dedicated to improving outcomes for transplant patients and advancing organ health. The Company’s integrated solutions include non‑invasive molecular testing for heart, kidney, and lung transplants; laboratory products; digital health technologies; and patient solutions that support care before and after transplant. CareDx is the leading provider of genomics‑based information for transplant patients
About EuroBio Scientific
Eurobio Scientific is a major player in the field of specialty in vitro diagnostics. It is involved in everything from research to the marketing of diagnostic tests in the fields of transplantation, immunology, and infectious diseases, and offers reagents for research laboratories, including pharmaceutical and biotechnology companies. With its numerous partnerships and strong hospital presence, Eurobio Scientific has its own extensive distribution network and a portfolio of proprietary products
